OptimAbs is a unique range of Therapeutic Drug Monitoring assays that can measure both serum biologics levels and antibodies against these biologics. It provides valuable information to help guide your treatment decisions for IBD patients treated by biologics.

OptimAbs assays are available for eight biologic drugs used to treat patients with inflammatory bowel disease (IBD):

  • OptimAbs Adalimumab (Humira®)
  • OptimAbs Certolizumab pegol (Cimzia®)
  • OptimAbs Golimumab (Simponi®)
  • OptimAbs Infliximab (Remicade®)
  • OptimAbs Infliximab-dyyb (Inflectra®)
  • OptimAbs Infliximab-abda (Renflexis®)
  • OptimAbs Ustekinumab (Stelara®)
  • OptimAbs Vedolizumab (Entyvio®)

About us

OptimAbs as an expert in inflammatory diseases plays α leading role in delivering diagnostic tools to help measure Biotherapies and their relative anti-drug antibodies concentrations within the blood flow.

More information

Clinically Relevant

OptimAbs helps you to maintain patients under treatment and support the proper use of Biotherapies.

More information


OptimAbs provides fast, reliable results that you can count on for the monitoring of patients under Biotherapies.

More information